Belatamab Mafodotin: Improved Survival in Lenalidomide-Refractory Patients

Summary of DREAMM-7⁢ Trial Results⁣ for Lenalidomide-Refractory Multiple Myeloma

This text details the results of the DREAMM-7 phase 3 trial, focusing on patients wiht relapsed/refractory multiple myeloma (RRMM) who⁢ where specifically refractory to lenalidomide. Here’s a breakdown of the key findings:

Trial⁤ Design:

* Comparison: Belantamab mafodotin + Bortezomib +‍ Dexamethasone (BVd) vs. Daratumumab + Bortezomib + Dexamethasone (DVd)
* Patient Population: RRMM patients, randomized 1:1.A significant portion (around half) had received one prior line of therapy,with a substantial percentage (33.6%) being refractory to lenalidomide.
* Treatment: 8 cycles of BVd or DVd, ⁢followed by⁤ belantamab mafodotin monotherapy in the BVd arm.

Key Results (specifically ⁢for lenalidomide-refractory patients):

* Progression-Free Survival (PFS): BVd showed considerably superior PFS – median of 35.7 months vs. 13.5 months with DVd (HR 0.39, 95% CI 0.17-0.88). 24-month PFS rates were 67% (BVd) vs. 35% (DVd).
* Overall Survival (OS): BVd demonstrated⁢ a trend towards improved OS, although it wasn’t statistically significant at ‍the⁤ data cutoff. Median OS was not reached with BVd (95% CI, 35.7 month-NE) compared to 35.4 months with ‍DVd (95% CI, 24.4 month-NE; HR, ⁤0.64; 95% CI, 0.26-1.59). At 36 months, OS was 74% with BVd vs. 50% with DVd.
* Duration of Response (DOR): DVd showed superiority in DOR, with a median of 13.1 months compared to BVd which ⁣had not yet been reached.

Conclusion:

The study suggests that BVd ⁣(belantamab mafodotin, bortezomib, and dexamethasone) offers a promising treatment option⁤ for patients with RRMM who are refractory ⁣to lenalidomide, particularly demonstrating favorable PFS and early, sustained OS benefits. The authors suggest BVd should be considered as a ‍potential new standard of⁣ care for this patient population.